IPCA Laboratories Limited
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic t… Read more
IPCA Laboratories Limited (IPCALAB) - Total Liabilities
Latest total liabilities as of September 2025: ₹33.97 Billion INR
Based on the latest financial reports, IPCA Laboratories Limited (IPCALAB) has total liabilities worth ₹33.97 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
IPCA Laboratories Limited - Total Liabilities Trend (2005–2025)
This chart illustrates how IPCA Laboratories Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
IPCA Laboratories Limited Competitors by Total Liabilities
The table below lists competitors of IPCA Laboratories Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Infrastrutture Wireless Italiane S.p.A
PINK:IFSUF
|
USA | $6.80 Billion |
|
Jumbo S.A.
AT:BELA
|
Greece | €272.34 Million |
|
Weihai Guangwei Composites Co Ltd
SHE:300699
|
China | CN¥3.09 Billion |
|
Envestnet Inc
NYSE:ENV
|
USA | $1.30 Billion |
|
Vodacom Group Ltd PK
PINK:VDMCY
|
USA | $146.48 Billion |
|
Rubis SCA
PA:RUI
|
France | €3.62 Billion |
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
China | CN¥860.37 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down IPCA Laboratories Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.10 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how IPCA Laboratories Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for IPCA Laboratories Limited (2005–2025)
The table below shows the annual total liabilities of IPCA Laboratories Limited from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹33.72 Billion | -0.06% |
| 2024-03-31 | ₹33.74 Billion | +24.46% |
| 2023-03-31 | ₹27.11 Billion | +30.23% |
| 2022-03-31 | ₹20.82 Billion | +53.96% |
| 2021-03-31 | ₹13.52 Billion | -16.47% |
| 2020-03-31 | ₹16.19 Billion | +14.58% |
| 2019-03-31 | ₹14.13 Billion | -1.12% |
| 2018-03-31 | ₹14.29 Billion | -5.02% |
| 2017-03-31 | ₹15.04 Billion | -7.86% |
| 2016-03-31 | ₹16.33 Billion | +1.78% |
| 2015-03-31 | ₹16.04 Billion | +28.22% |
| 2014-03-31 | ₹12.51 Billion | +9.42% |
| 2013-03-31 | ₹11.43 Billion | +6.51% |
| 2012-03-31 | ₹10.73 Billion | +24.68% |
| 2011-03-31 | ₹8.61 Billion | +14.89% |
| 2010-03-31 | ₹7.49 Billion | +1.09% |
| 2009-03-31 | ₹7.41 Billion | +29.80% |
| 2008-03-31 | ₹5.71 Billion | +31.90% |
| 2007-03-31 | ₹4.33 Billion | +18.52% |
| 2006-03-31 | ₹3.65 Billion | +1.24% |
| 2005-03-31 | ₹3.61 Billion | -- |